The JAK-STAT Pathway in Inflammatory Bowel Disease

Expert Insights and Discussion of the Latest Research

This course was last updated on
June 28, 2017
CME credit has expired.
Enter your information to begin.

Russell D. Cohen, MD, and Thomas A. Ullman, MD, summarize clinical data on JAK inhibitors in inflammatory bowel disease (IBD). In addition to discussing the rationale for targeting JAK-STAT signaling pathways, faculty discuss the clinical implications of new research for patients with IBD.

Watch videos on new data and expert analysis. Each video is 7-9 minutes. Proceed at your own pace and in any order.

Compare your knowledge with your peers.

Download a print-friendly version of the entire activity.

Incorporate slides into your library.

Content Areas

  • IBD pathogenesis
  • JAK-STAT signaling
  • JAK inhibitors in ulcerative colitis
  • JAK inhibitors in Crohn's disease
  • Clinical implications

Target Audience

This activity was developed for gastroenterologists, gastroenterology fellows, and other health care professionals who have an interest in inflammatory bowel disease (Crohn's disease and ulcerative colitis).


Russell D. Cohen, MD
Russell D. Cohen, MD
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
The University of Chicago Medicine
Chicago, Illinois
Thomas A. Ullman, MD
Thomas A. Ullman, MD
Senior Associate Dean for Clinical Affairs
Professor of Medicine
The Dr. Henry D. Janowitz Division of Gastroenterology
Chief Medical Officer
Mount Sinai Doctors Faculty Practice
Icahn School of Medicine at Mount Sinai
New York, New York
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
Opens: June 28, 2017
Expires: June 27, 2018
Target Audience: Gastroenterologists
Other Health Care Providers
This activity is supported by an independent educational grant from Pfizer.